Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJonathan C. PattonRORebecca OwensVGVikas A. Gupta

Discussion

Loading...

Member takes

Overview

Inhibition of NSD2 increases mitochondrial priming in t(4;14) myeloma cell lines, suggesting targeted therapy potential.

Key Points

  • To examine the effects of NSD2 inhibition on mitochondrial priming in t(4;14) myeloma cells.
  • Dynamic BH3 profiling conducted on multiple t(4;14) myeloma cell lines after NSD2 inhibition.
  • Cell viability assessed through Annexin V staining and flow cytometry.
  • Changes in cytochrome c due to NSD2 inhibition measured by BH3 profiling.
  • MCL1 priming increased in H929 after NSD2 inhibition, showing 30% sensitivity to MCL1 inhibitor AZD5991.
  • Other cell lines demonstrated varying degrees of mitochondrial priming changes.
  • KMS18 cells displayed negative delta priming, indicating decreased sensitivity following NSD2 inhibition.

Cite This Study

Patton et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236de89https://doi.org/10.1182/blood-2025-2177
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma2025
  2. 2NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma2025
  3. 3NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma2026
  4. 4Abstract 1939: Oncogenic NSD2 drives Eph-ephrin signaling between myeloma and bone marrow stromal cells.2026
  5. 5Pathogenic Mechanisms Activated by NSD2 Translocations in Multiple Myeloma2024